Month: March 2023

EB1 is a MNK Kinase Inhibitor and Selectively Inhibits the Growth of Cancer Cells

MNKs (Mitogen-activated protein kinase interacting kinases) belong to the family of Ser/Thr kinases, and are classified as members of Ca2+/calmodulin-dependent kinases. MNKs have two different isoforms (MNK1 and MNK2) and play critical roles in the development of human malignancies. MNK1 and MNK2 execute a unique function in regulating eIF4E...

MPT0B014, a Tubulin Polymerization Inhibitor Induces Cancer Cell Apoptosis

Microtubules are polymers of microtubule proteins that form part of the cytoskeleton and provide structure and shape for eukaryotic cells. Specifically, Microtubules play an important role in many cellular processes. They participate in maintaining cellular structure and form the cytoskeleton together with microfilaments and intermediate filaments. Besides, Microtubes are...

dBRD9 is a PROTAC and can Selective Degrades BRD9

BRD9 is a subunit of the human BAF (SWI/SNF) nucleosome remodeling complex. Besides, BRD9 contains a bromodomain and is closely related to BRD7. Importantly, The BRD9 gene is frequently present in variable copy numbers in lung cancer and has emerged as an attractive therapeutic target in cancer. Moreover, the...

MC0704 is a STAT3 Inhibitor for Triple-negative Breast Cancer Research

Breast cancer (BC) is one of the main causes of cancer-associated death in women. And, BC is high recurrence and/or metastatic potential. BC is typically categorized into respective subtypes based on the presence of representative receptors (the human epidermal growth factor receptor, estrogen receptor, and progesterone receptor). Hence, these...

Palbociclib is an Orally Active CDK4 and CDK6 Inhibitor for Cancer Research

Cyclin-dependent kinases (CDKs) are serine/threonine kinases whose activity depends on a regulatory subunit-a cyclin. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa. What’s more, CDKs play important roles in the control of cell division and modulate transcription in response to several extra- and...

Izalontamab (SI-B001) is a Bispecific Anti-EGFR/HER3 mAb for Cancer Research

EGFR (epidermal growth factor receptor) is a member of the ErbB receptor family1. Besides, EGFR is a common therapeutic strategy in epithelioma such as lung adenocarcinoma, colon cancer, head and neck cancer, and esophageal cancer, where the over-expression of EGFR caused by gene mutation plays an essential role in...